Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial.

Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H.

Dement Geriatr Cogn Dis Extra. 2015 Apr 10;5(1):135-46. doi: 10.1159/000375527. eCollection 2015 Jan-Apr.


Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease.

Kim YK, Lim KB, Lee SC, Park JW, Lee HJ, Kwon BS, Lee HJ.

Dement Geriatr Cogn Dis Extra. 2014 Oct 29;4(3):395-401. doi: 10.1159/000363622. eCollection 2014 Sep.


Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

Herrmann N, Lanctôt KL, Hogan DB.

Alzheimers Res Ther. 2013 Jul 8;5(Suppl 1):S5. doi: 10.1186/alzrt201. Epub 2013 Jul 8.


A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12r01412. doi: 10.4088/PCC.12r01412. Epub 2013 Mar 7.


Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice.

López-Pousa S, Arranz FJ.

Patient Prefer Adherence. 2013;7:47-54. doi: 10.2147/PPA.S38719. Epub 2013 Jan 10.


Broader considerations of higher doses of donepezil in the treatment of mild, moderate, and severe Alzheimer's disease.

Berk C, Sabbagh M.

Int J Alzheimers Dis. 2012;2012:707468. doi: 10.1155/2012/707468. Epub 2011 Dec 1.


Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.

Wallin AK, Wattmo C, Minthon L.

Neuropsychiatr Dis Treat. 2011;7:565-76. doi: 10.2147/NDT.S24196. Epub 2011 Sep 30.


Predictors of long-term cognitive outcome in Alzheimer's disease.

Wattmo C, Wallin AK, Londos E, Minthon L.

Alzheimers Res Ther. 2011 Jul 20;3(4):23. doi: 10.1186/alzrt85.


Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.

Lam B, Hollingdrake E, Kennedy JL, Black SE, Masellis M.

Hum Genomics. 2009 Dec;4(2):91-106. Review.


Progress update: Pharmacological treatment of Alzheimer's disease.

Hogan DB.

Neuropsychiatr Dis Treat. 2007;3(5):569-78.


Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Cacabelos R.

Neuropsychiatr Dis Treat. 2007 Jun;3(3):303-33.


Rivastigmine in the treatment of patients with Alzheimer's disease.

Müller T.

Neuropsychiatr Dis Treat. 2007 Apr;3(2):211-8.


Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, Lane R.

Curr Alzheimer Res. 2009 Feb;6(1):4-14.


Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.

Herrmann N, Gauthier S.

CMAJ. 2008 Dec 2;179(12):1279-87. doi: 10.1503/cmaj.070804. Review.


Does analysis using "last observation carried forward" introduce bias in dementia research?

Molnar FJ, Hutton B, Fergusson D.

CMAJ. 2008 Oct 7;179(8):751-3. doi: 10.1503/cmaj.080820. No abstract available.


Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.

Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE.

Clin Interv Aging. 2008;3(2):211-25. Review.


Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.

Annicchiarico R, Federici A, Pettenati C, Caltagirone C.

Ther Clin Risk Manag. 2007 Dec;3(6):1113-23.


Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease.

Geula C, Nagykery N, Nicholas A, Wu CK.

J Neuropathol Exp Neurol. 2008 Apr;67(4):309-18. doi: 10.1097/NEN.0b013e31816a1df3.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk